Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining. Bicarbonate, a crucial component of the mucosal-bicarbonate barrier, is vital in neutralizing stomach acid. A decline in bicarbonate production can tip the delicate balance, leading to an acidic environment within the stomach. This acidic milieu, in turn, inflicts injury upon the stomach lining, thereby setting the stage for the development of peptic ulcer disease.

Helicobacter pylori, a gram-negative bacillus, can further exacerbate the situation. This microbial invader interferes with somatostatin production, a hormone regulating acid secretion. As a result, there is an upsurge in gastric acid production and a simultaneous decrease in bicarbonate production, crippling the body's defense barrier. This tandem effect ultimately leads to the impairment of the mucosal-bicarbonate barrier and contributes to PUD development.

Prostaglandins, another essential player in this complex orchestra, support the gastric mucosa. They serve as champions of cytoprotection by increasing bicarbonate secretion and reducing gastric acid output. Their role is instrumental in maintaining the health and integrity of the gastric lining.

In pharmacotherapy, nonsteroidal anti-inflammatory drugs (NSAIDs) wield significant influence. While these medications are prized for their pain-relieving properties, they pose a risk to the mucosal-bicarbonate barrier. NSAIDs inhibit prostaglandin production, reducing gastric mucus secretion and mucosal blood flow. These alterations create an environment conducive to PUD development.

Chronic PUD often arises due to various disturbances in the gastrointestinal system. Factors such as duodenogastric reflux and atrophic gastritis can weaken the mucosal-bicarbonate barrier, rendering it vulnerable to the erosive effects of gastric acid and pepsin.

Dal capitolo 21:

article

Now Playing

21.2 : Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Drugs for Peptic Ulcer Disease

254 Visualizzazioni

article

21.1 : Fisiopatologia dell'ulcera peptica: fattori dannosi

Drugs for Peptic Ulcer Disease

397 Visualizzazioni

article

21.3 : Farmaci soppressori dell'acido per l'ulcera peptica: inibitori della pompa protonica

Drugs for Peptic Ulcer Disease

251 Visualizzazioni

article

21.4 : Farmaci soppressori dell'acido per l'ulcera peptica: antagonisti del recettore H2 dell'istamina

Drugs for Peptic Ulcer Disease

313 Visualizzazioni

article

21.5 : Farmaci soppressori dell'acido per l'ulcera peptica: antiacidi

Drugs for Peptic Ulcer Disease

228 Visualizzazioni

article

21.6 : Farmaci per l'ulcera peptica: sucralfato come agenti protettivi della mucosa

Drugs for Peptic Ulcer Disease

203 Visualizzazioni

article

21.7 : Farmaci per l'ulcera peptica: analoghi delle prostaglandine come agenti protettivi della mucosa

Drugs for Peptic Ulcer Disease

205 Visualizzazioni

article

21.8 : Trattamento dell'Helicobacter pylori nelle ulcere peptiche: terapia antimicrobica

Drugs for Peptic Ulcer Disease

207 Visualizzazioni

JoVE Logo

Riservatezza

Condizioni di utilizzo

Politiche

Ricerca

Didattica

CHI SIAMO

Copyright © 2025 MyJoVE Corporation. Tutti i diritti riservati